• Advancing gastrointestinal health naturally

    Our Gastrointestinal Reprogramming Product (GaRP) product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders.

  • Exclusive Global License Agreement with Zoetis

    Anatara has signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach. More >>

Company description

Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach is a natural product that has been shown to aid in the control of scour in piglets. Anatara has signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

Video overview

Latest news All news

  • Change in Substantial Holding

    Form 604 – Notice Of Change Of Interests Of Substantial Holder was released to the ASX on 17th August 2018.

    Please click here to view the ASX announcement.

  • New PAC Partners Research Report

    PAC Partners Research has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.

    Restore human gut health with GaRP

    Please open the attached PDF to view the report.

Investors

Investors Home

Pause